MA31032B1 - Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives. - Google Patents

Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives.

Info

Publication number
MA31032B1
MA31032B1 MA32053A MA32053A MA31032B1 MA 31032 B1 MA31032 B1 MA 31032B1 MA 32053 A MA32053 A MA 32053A MA 32053 A MA32053 A MA 32053A MA 31032 B1 MA31032 B1 MA 31032B1
Authority
MA
Morocco
Prior art keywords
medicaments
production
treatment
neurodegenerative diseases
neuroprotective compounds
Prior art date
Application number
MA32053A
Other languages
English (en)
Inventor
Ridant Alain Le
Catherine Harpey
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA31032B1 publication Critical patent/MA31032B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UTILISATION DE COMPOSÉS NEUROPROTECTEURS POUR L'OBTENTION DE MÉDICAMENTS DESTINÉS AU TRAITEMENT CURATIF DES MALADIES NEURODÉGÉNÉRATIVES ET/OU À LA PRÉVENTION DE L'APPARITION DES TROUBLES DÉCOULANT DE CES MALADIES
MA32053A 2007-01-05 2009-06-29 Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives. MA31032B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0700048A FR2911143A1 (fr) 2007-01-05 2007-01-05 Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives.

Publications (1)

Publication Number Publication Date
MA31032B1 true MA31032B1 (fr) 2009-12-01

Family

ID=38309971

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32053A MA31032B1 (fr) 2007-01-05 2009-06-29 Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives.

Country Status (14)

Country Link
US (1) US20090298813A1 (fr)
EP (1) EP2101768A2 (fr)
JP (1) JP2010514827A (fr)
KR (1) KR20090104853A (fr)
CN (1) CN101578100A (fr)
AR (1) AR064749A1 (fr)
AU (1) AU2008214550A1 (fr)
BR (1) BRPI0806275A2 (fr)
CA (1) CA2674100A1 (fr)
EA (1) EA200900923A1 (fr)
FR (1) FR2911143A1 (fr)
MA (1) MA31032B1 (fr)
MX (1) MX2009007198A (fr)
WO (1) WO2008099083A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926077A1 (fr) * 2008-01-04 2009-07-10 Servier Lab Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP6154282B2 (ja) * 2013-10-03 2017-06-28 株式会社ファンケル 神経幹細胞又は神経前駆細胞の増殖促進剤
CN111018802B (zh) * 2019-12-03 2021-07-06 湖北大学 具有抗帕金森氏症的化合物、制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA786426B (en) * 1977-11-25 1979-10-31 Scras New indulo(2,3-a)quinolizidines,preparation and therapeutic use
FR2713644B1 (fr) * 1993-12-14 1996-02-09 Adir Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP1470818B1 (fr) * 2003-04-25 2006-07-26 Neuro3D Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP
CN1566099A (zh) * 2003-06-13 2005-01-19 中国科学院上海药物研究所 异喹啉－1,3,4－三酮类化合物、制备方法及其用途

Also Published As

Publication number Publication date
US20090298813A1 (en) 2009-12-03
BRPI0806275A2 (pt) 2011-09-06
EA200900923A1 (ru) 2009-12-30
JP2010514827A (ja) 2010-05-06
MX2009007198A (es) 2009-08-12
WO2008099083A2 (fr) 2008-08-21
EP2101768A2 (fr) 2009-09-23
WO2008099083A3 (fr) 2008-12-11
AU2008214550A1 (en) 2008-08-21
CA2674100A1 (fr) 2008-08-21
FR2911143A1 (fr) 2008-07-11
CN101578100A (zh) 2009-11-11
KR20090104853A (ko) 2009-10-06
AR064749A1 (es) 2009-04-22

Similar Documents

Publication Publication Date Title
MA46018A (fr) Activateurs d'édition du génome
MA31767B1 (fr) Composes organiques et leurs utilisations
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
MA31842B1 (fr) Procédés de traitement de l'obésité et de maladies et de troubles associés à l'obésité
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
MA33753B1 (fr) Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
WO2009010454A3 (fr) Nouveaux dérivés amido et leur utilisation en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
FR15C0046I2 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
WO2007089557A3 (fr) Composés et compositions utilisés comme modulateurs de ppar
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
TW200602330A (en) Compounds and compositions as PPAR modulators
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione
WO2009071690A3 (fr) Dérivés d'oxindole à double substitution en positions 5 et 6 et leur utilisation pour traiter des maladies liées à la vasopressine
MA28987B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
MX2012002725A (es) Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las misma.
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
TW200735868A (en) Compositions and methods for treating CNS disorders
MA31032B1 (fr) Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives.